Medication info

Y2SOme Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Seongyi Bio Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202106814 · Approved 2021.10.07

Summary

Main use
Treatment and prevention of gastroesophageal reflux disease, gastrointestinal disorders (ulcers, etc.), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (non-COX-2-selective or COX-2-selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment No dose adjustment is necessary. Since there is limited experience with administration to patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years — There is no experience with administration of this medicine to children under 12 years.

Ingredients

Manufacturer
Seongyi Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of gastroesophageal reflux disease, gastrointestinal disorders (ulcers, etc.), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, especially erosive reflux esophagitis, and to prevent the recurrence of esophagitis. It also aids in treating or preventing recurrence of ulcers in the duodenum and stomach caused by Helicobacter pylori. It is effective in treating gastrointestinal symptoms or gastric ulcers caused by non-steroidal anti-inflammatory drugs. It is also used for the treatment of Zollinger-Ellison syndrome and for maintenance therapy after the prevention of rebleeding from gastric and duodenal ulcers. In summary, this medication is effectively used to treat various symptoms and diseases related to gastrointestinal disorders and ulcers.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (non-COX-2-selective or COX-2-selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment No dose adjustment is necessary. Since there is limited experience with administration to patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years — There is no experience with administration of this medicine to children under 12 years.

Precautions

This drug should not be administered to patients who are allergic to certain components or have experienced hypersensitivity reactions. Additionally, caution is required as allergic reactions may occur when used with certain antibiotics. Patients with heart disease or those who are nursing should not take this drug. Various side effects may occur, with symptoms such as headache, abdominal pain, and diarrhea being common. Rarely, severe side effects such as blood abnormalities, neurological issues, and skin rashes have been reported. Regular checkups are necessary with prolonged use, and if symptoms worsen or new symptoms appear, immediate consultation with a physician is required. This drug may interact with other medications, so it is essential to inform healthcare providers about any other medications being taken. Caution is especially needed when used together with some antivirals or anticoagulants. Safety during pregnancy has not been fully established, so pregnant women should consult a doctor before taking this medication. Nursing mothers are advised against taking this drug. In case of overdose, there is no specific antidote, so immediate medical attention should be sought. This medication should be stored out of reach of children and should not be transferred to other containers.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorder, pharyngeal disorder, rectal disorder, gastrointestinal symptoms, increased serum gastrin, tongue disorder, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, bilirubinemia, liver function abnormality, elevated ALT, elevated AST, diabetes, hyperuricemia, elevated ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, appetite loss, apathy, increased appetite, confusion, exacerbation of depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorder, tremor, visual field loss, dysmenorrhea, menstrual disorder, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papulovesicular rash, otitis media, dysosmia, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual abnormalities, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric mucous gland polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.